KALV: 15-12G · other
KalVista Pharmaceuticals filed a Form 15 to terminate the registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934 and to suspend its duty to file reports. The company cited Rule 12h-3(b)(1)(i) and Rule 12g-4(a)(1) as the basis for this action, noting that the approximate number of holders of record is one. This filing indicates that the company will no longer be required to submit periodic reports to the SEC, signaling a significant reduction in public transparency and likely a move to go private.
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
Chiesi Group completed its acquisition of KalVista Pharmaceuticals, resulting in the delisting of KALV shares from the Nasdaq Global Market. The transaction closed via a merger following a tender offer that accepted approximately 77.8% of outstanding shares for $27.00 per share in cash. All remaining outstanding shares were converted into the right to receive the same $27.00 per share, and KalVista is now a wholly owned subsidiary of Chiesi.
KALV: SC TO-T/A · acquisition merger
Chiesi Farmaceutici S.p.A. has cleared all major regulatory hurdles for its $27.00 per share cash acquisition of KalVista Pharmaceuticals, Inc. The US HSR waiting period expired on May 28, 2026, German antitrust authorities cleared the deal on May 27, 2026, and the Italian FDI Authority confirmed it will not object on May 29, 2026. Despite these clearances, the transaction faces legal challenges. KalVista has received twelve demand letters alleging disclosure deficiencies in the Schedule 14D-9, and two individual lawsuits have been filed in New York Supreme Court seeking to enjoin the merger. The acquirer believes these claims are without merit but acknowledges the risk of further litigation.
KALV: SC 14D9/A · acquisition merger
KalVista Pharmaceuticals has filed an amendment to its Schedule 14D-9, recommending that shareholders accept Chiesi Farmaceutici’s tender offer of $27.00 per share in cash. This filing supplements the original recommendation with detailed background on the negotiation process, including rejected lower bids and a contingent value right (CVR) proposal that was ultimately replaced by a higher all-cash offer. The amendment includes updated financial projections and a fairness opinion from Centerview Partners, which utilized public company comparables, precedent transactions, and discounted cash flow analysis to support the deal value. Centerview’s analysis implies an equity value range of $13.65 to $27.50 per share, validating the $27.00 offer price as fair to shareholders. The filing also discloses two stockholder lawsuits challenging the adequacy of the disclosure in the original 14D-9, alleging negligent misrepresentation. KalVista asserts these claims are without merit and filed the amendment voluntarily to moot the allegations. Regulatory hurdles, including HSR and German antitrust reviews, have been cleared or expired.
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
KalVista presented new real-world data at ISPOR and the Eastern Allergy Conference highlighting the significant burden of injectable on-demand treatments for children aged 2-11 with hereditary angioedema (HAE). The data reveals that nearly half of children did not receive treatment for their most recent attack, and 90% of caregivers reported anxiety about administering injectable therapies, with needle fear and pain cited as primary barriers. These findings reinforce the clinical and commercial value of EKTERLY (sebetralstat), the first oral on-demand HAE therapy, as the company prepares to submit a new drug application for pediatric use in Q3 2026.
Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC issued a shareholder-solicitation notice naming KALV and three other companies; no new disclosure from the company itself. The release is a routine lead-plaintiff-deadline reminder soliciting investors with losses to contact the firm on a contingency basis. This is law-firm marketing, not an issuer disclosure or a court action; treat as low-signal noise.
KALV: 10-Q · periodic report
KalVista Pharmaceuticals reported $40.9 million in total revenue for the first quarter ended March 31, 2026, driven by $39.2 million in product sales of its approved therapy EKTERLY. The company posted a net loss of $23.5 million, or $0.43 per share, as it scales commercial operations for its lead asset in hereditary angioedema. In a subsequent event disclosed in the filing, KalVista entered into a definitive merger agreement with Chiesi Farmaceutici S.p.A. on April 29, 2026. Chiesi has commenced a tender offer to acquire all outstanding shares for $27.00 per share in cash, with the offer expiring on June 10, 2026. The transaction is expected to close in the third quarter of 2026, after which KalVista will become a wholly owned subsidiary of Chiesi and its stock will delist. The agreement includes a $66.4 million termination fee payable by KalVista under certain circumstances, reflecting the significant commitment and risk associated with the pending deal.
Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC announced an investigation into KalVista Pharmaceuticals regarding its proposed sale to Chiesi Group for $27.00 per share in cash. The firm is examining potential violations of federal securities laws or breaches of fiduciary duty relating to the transaction terms and potential consideration. This release is a solicitation encouraging shareholders to contact the firm on a contingency fee basis to discuss their rights and options.
Are KALV, TBRG, UNF, ESQ Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC is investigating the board of Esquire Financial Holdings for potential breaches of fiduciary duty related to its merger with Signature Bancorporation. The investigation centers on whether the transaction contains terms that could prevent superior offers or otherwise disadvantage shareholders compared to insiders. Shareholders are advised to contact the firm to discuss their rights and options regarding the proposed deal.
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio
KalVista Pharmaceuticals agreed to be acquired by Chiesi Group for $27.00 per share in cash, representing a total equity value of approximately $1.9 billion. The purchase price represents a 36% premium to KalVista's 30-day volume-weighted average share price as of April 28, 2026, and the transaction is expected to close in Q3 2026. The acquisition adds EKTERLY (sebetralstat), an oral on-demand treatment for hereditary angioedema, to Chiesi's rare immunology portfolio; the drug generated $49 million in sales in 2025 following its US launch.
